Application No.: 10/688,059 2 Docket No.: 000166.2025-US02

AMENDMENTS TO THE CLAIMS

(Currently amended) A composition for the sustained release of a
biologically active polypeptide consisting essentially of: a
biocompatible polylactide-co-glycolide polymer having dispersed
therein a biologically active glucoregulatory polypeptide, a sugar and
glycine.

- 2. (Previously presented) The composition of claim 1, wherein the polypeptide is selected from GLP-1, GLP-2, exendin-3, exendin-4 or a combination thereof.
- 3. (Previously presented) The composition of claim 2, wherein the polypeptide is present from about 0.01% (w/w) to about 50% (w/w) of the total weight of the composition.
- 4. (Previously presented) The composition of claim 3, wherein the polypeptide is present in a range from about 0.1% (w/w) to about 30% (w/w) of the total weight of the composition.
- 5. (Previously presented) The composition of claim 4, wherein the polypeptide is present from about 0.1% (w/w) to about 10% (w/w) of the total weight of the composition.
- 6. (Previously presented) The composition of claim 5, wherein the polypeptide is present from about 0.5% (w/w) to about 5% (w/w) of the total weight of the composition.
- 7. (Previously presented) The composition of claim 1, wherein the sugar is present from about 0.01% (w/w) to about 50% w/w of the total weight of the composition.
- 8. (Previously presented) The composition of claim 7, wherein the sugar is present from about 0.01% (w/w) to about 10% w/w of the total weight of the composition.
- 9. (Previously presented) The composition of claim 8, wherein the sugar is present from about 0.01% (w/w) to about 5% w/w of the total weight of the composition.

Application No.: 10/688,059 3 Docket No.: 000166.2025-US02

10. (Previously presented) The composition of claim 1, wherein the sugar is selected from a monosaccharide, a disaccharide, a sugar alcohol or a combination thereof.

- 11. (Previously presented) The composition of claim 10, wherein the sugar is selected from sucrose, trehalose, mannitol and combinations thereof.
- 12. (Previously presented) The composition of claim 10, wherein the sugar is a disaccharide.
- 13. (Previously presented) The composition of claim 12, wherein the disaccharide is sucrose, trehalose or a combination thereof.
- 14. (Cancelled)
- 15. (Cancelled)
- 16. (Cancelled)
- 17. (Cancelled)
- 18. (Withdrawn) A method of treating a patient suffering from Type 2 diabetes comprising administering a therapeutically effective amount of a sustained release composition according to claim 1.
- 19. (Currently amended) A method of treating a patient suffering from Type 2 diabetes comprising administering a therapeutically effective amount of a sustained release composition according to claim 22[[14]].
- 20. (New) The composition of claim 1, wherein the polypeptide is exendin-4.
- 21. (New) The composition of claim 1, wherein the sugar is sucrose.
- 22. (New) The composition of claim 1, wherein the polypeptide is exendin-4 and the sugar is sucrose.